Register Login

Pieris Pharmaceuticals Inc. (PIRS)

(90% Positive) Pieris Pharmaceuticals Inc. (PIRS) Announces Enrollment Update for contained Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 30, 2026, 8:19 a.m.

    📋 Pieris Pharmaceuticals Inc. (PIRS) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 07:00:36

    Event Type: Clinical Trial Update

    Event Details:

    Pieris Pharmaceuticals Inc. (PIRS) Announces Clinical Trial Update Pieris Pharmaceuticals Inc. (PIRS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: contained, framework
    • Diseases/Conditions: some cases
    • Clinical Stage: clinical trial
    • Collaboration: Company
      • Targeting the Causal Mevalonate Pathway Target: Mevalonate Pathway Tissue: Epidermis & Dermis Site of pathogenesis-directed therapy An on-target, in-tissue approach could result in significant clinical improvement *HMGCR = 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Image sources: Milani D, Warbasse E, Chen WS. Porokeratosis. PathologyOutlines.com website. * Using QTORIN™, we considered and tested a wide range of mevalonate pathway inhibitors QTORIN™ Pitavastatin: On Target, In Tissue QTORIN™ PITAVASTATIN Molecule Potency Optimal Skin PK Stability Pitavastatin Mev. Inhibitor 2 Mev. Inhibitor 3 Mev. Inhibitor 4 Mev. Inhibitor 5 Mev. Inhibitor 6 Mev. Inhibitor 7 Did not meet some or all pre-defined target product attributes Pitavastatin is an FDA-approved next-generation oral statin for patients with primary hyperlipidemia and mixed dyslipidemia Superior inhibition of the mevalonate pathway compared to all molecules evaluated Key characteristics: Payload: > 2% concentration achieved Dermal penetration: in vitro penetration test confirms > IC90 Low systemic absorption Encouraging preliminary drug stability IP: Filed formulation & method of use IP and licensed Yale IP QTORIN™ Pitavastatin Clinical Pathway: Planned Initiation of Phase 2 in 2H 2026
      • Targeting announcement in 2026
      • Anticipated By YE 2026

    🔬 Clinical Development Pipeline (Pieris Pharmaceuticals Inc.):

    Product Type Development Stage Therapeutic Area Source
    Angiocal® (PRS-050-PEG40) DRUG Phase PHASE1 Solid Tumor ClinicalTrials.gov
    SP-420 DRUG Phase PHASE1 Iron Overload ClinicalTrials.gov
    PRS-080-Placebo#001 DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    PRS-080#022-DP DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Cinrebafusp alfa (PRS-343) in combination with tucatinib DRUG Phase PHASE2 HER2-positive Gastric Cancer ClinicalTrials.gov
    Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel DRUG Phase PHASE2 HER2-positive Gastric Cancer ClinicalTrials.gov
    PRS-343 in Combination with Atezolizumab DRUG Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov
    PRS-343 DRUG Phase PHASE1 HER2-positive Breast Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Pieris Pharmaceuticals Inc.
    • Ticker Symbol: PIRS

Search

News categories